Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer

References

• Kaplan JM. Adenovirus-based cancer gene therapy. Curr. Gene Ther.5(6), 595–605 (2005).
   PubMed Web of Science ®Google Scholar
• Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta1785(2), 217–231 (2008).
   PubMed Web of Science ®Google Scholar
• Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer9(1), 64–71 (2009).
   PubMed Web of Science ®Google Scholar
• Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther.9(17), 2577–2583 (1998).
   PubMed Web of Science ®Google Scholar
• Stone D, Lieber A. New serotypes of adenoviral vectors. Curr. Opin. Mol. Ther.8(5), 423–431 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson JM, Engelhardt JF, Grossman M et al. Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a Phase I trial. Hum. Gene Ther.5(4), 501–519 (1994).
   PubMed Web of Science ®Google Scholar
• Crystal RG, McElvaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet.8(1), 42–51 (1994).
   PubMed Web of Science ®Google Scholar
• Crystal RG, Hirschowitz E, Lieberman M et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther.8(8), 985–1001 (1997).
   PubMed Web of Science ®Google Scholar
• Sterman DH, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Ther.9(7), 1083–1092 (1998).
   PubMed Web of Science ®Google Scholar
• Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol.4(2), 101–117 (2007).
   PubMedGoogle Scholar
• Fujiwara T. Telomerase-specific virotherapy for human squamous cell carcinoma. Expert Opin. Biol. Ther.9(3), 321–329 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol.3(1), 17–26 (2002).
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science274(5286), 373–376 (1996).
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med.6(8), 879–885 (2000).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Khuri F, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol.19(2), 289–298 (2001).
   PubMed Web of Science ®Google Scholar
• Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol.72(12), 9479–9490 (1998).
   PubMed Web of Science ®Google Scholar
• O’Shea CC, Johnson L, Bagus B et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell6(6), 611–623 (2004).
   PubMed Web of Science ®Google Scholar
• Maehara Y, Oshiro T, Endo K et al. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery119(4), 397–402 (1996).
   PubMed Web of Science ®Google Scholar
• Rivadeneira DE, Simmons RM, Christos PJ et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J. Am. Coll. Surg.191(1), 1–6 (2000).
   PubMedGoogle Scholar
• Chang GJ, Rodriguez-Bigas MA, Skibber JM et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J. Natl Cancer Inst.99(6), 433–441 (2007).
   PubMed Web of Science ®Google Scholar
• Volpe CM, Koo J, Miloro SM et al. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. J. Am. Coll. Surg.181(1), 56–64 (1995).
   PubMedGoogle Scholar
• Harrison LE, Karpeh MS, Brennan MF. Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. J. Gastrointest. Surg.2(2), 126–131 (1998).
   PubMedGoogle Scholar
• Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N. Engl. J. Med.359(5), 453–462 (2008).
   PubMed Web of Science ®Google Scholar
• Gotoda T, Sasako M, Ono H et al. Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br. J. Surg.88(3), 444–449 (2001).
   PubMedGoogle Scholar
• Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer33(5), 787–791 (1997).
   PubMed Web of Science ®Google Scholar
• Dong CK, Masutomi K, Hahn WC. Telomerase: regulation, function and transformation. Crit. Rev. Oncol. Hematol.54(2), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Hiyama K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol.155(8), 3711–3715 (1995).
   PubMed Web of Science ®Google Scholar
• Tahara H, Yasui W, Tahara E et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene18(8), 1561–1567 (1999).
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell2(4), 257–265 (2002).
   PubMed Web of Science ®Google Scholar
• Feng J, Funk WD, Wang SS et al. The RNA component of human telomerase. Science269(5228), 1236–1241 (1995).
   PubMed Web of Science ®Google Scholar
• Harrington L, McPhail T, Mar V et al. A mammalian telomerase-associated protein. Science275(5302), 973–977 (1997).
   PubMed Web of Science ®Google Scholar
• Meyerson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell90(4), 785–795 (1997).
   PubMed Web of Science ®Google Scholar
• Nakamura TM, Morin GB, Chapman KB et al. Telomerase catalytic subunit homologs from fission yeast and human. Science277(5328), 955–959 (1997).
   PubMed Web of Science ®Google Scholar
• Nakayama J, Tahara H, Tahara E et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet.18(1), 65–68 (1998).
   PubMed Web of Science ®Google Scholar
• Beattie TL, Zhou W, Robinson MO et al. Reconstitution of human telomerase activity in vitro. Curr. Biol.8(3), 177–180 (1998).
   PubMed Web of Science ®Google Scholar
• Keith WN, Sarvesvaran J, Downey M. Analysis of telomerase RNA gene expression by in situ hybridization. Methods Mol. Biol.19165–19181 (2002).
   Google Scholar
• Bilsland AE, Merron A, Vassaux G et al. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res.67(3), 1299–1307 (2007).
   PubMed Web of Science ®Google Scholar
• Wirth T, Zender L, Schulte B et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res.63(12), 3181–3188 (2003).
   PubMed Web of Science ®Google Scholar
• Lanson NA Jr, Friedlander PL, Schwarzenberger P et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res.63(22), 7936–7941 (2003).
   PubMed Web of Science ®Google Scholar
• Irving J, Wang Z, Powell S et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther.11(3), 174–185 (2004).
   PubMed Web of Science ®Google Scholar
• Kim E, Kim JH, Shin HY et al. Ad-mTERT-δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther.14(15), 1415–1428 (2003).
   PubMed Web of Science ®Google Scholar
• Huang TG, Savontaus MJ, Shinozaki K et al. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther.10(15), 1241–1247 (2003).
   PubMed Web of Science ®Google Scholar
• Zou W, Luo C, Zhang Z et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene23(2), 457–464 (2004).
   PubMed Web of Science ®Google Scholar
• Kuppuswamy M, Spencer JF, Doronin K et al. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther.12(22), 1608–1617 (2005).
   PubMed Web of Science ®Google Scholar
• Li Y, Yu DC, Chen Y et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res.61(17), 6428–6436 (2001).
   PubMed Web of Science ®Google Scholar
• Kawashima T, Kagawa S, Kobayashi N et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin. Cancer Res.10(1 Pt 1), 285–292 (2004).
   PubMed Web of Science ®Google Scholar
• Taki M, Kagawa S, Nishizaki M et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’). Oncogene24(19), 3130–3140 (2005).
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Watanabe Y, Shirakiya Y et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci.99(2), 385–390 (2008).
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the promoter. Curr. Cancer Drug Targets7(2), 191–201 (2007).
   PubMed Web of Science ®Google Scholar
• Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res.67(2), 429–432 (2007).
   PubMed Web of Science ®Google Scholar
• Burton JB, Johnson M, Sato M et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat. Med.14(8), 882–888 (2008).
   PubMed Web of Science ®Google Scholar
• Kishimoto H, Kojima T, Watanabe Y et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat. Med.12(10), 1213–1219 (2006).
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Watanabe Y, Onimatsu H et al. Telomerase-specific virotheranostics for human head and neck cancer. Clin. Cancer Res.15(7), 2335–2343 (2009).
   PubMedGoogle Scholar
• Kojima T, Watanabe Y, Hashimoto Y et al. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann. Surg.251(6), 1079–1086 (2010).
   PubMedGoogle Scholar
• Kawabata K, Sakurai F, Koizumi N et al. Adenovirus vector-mediated gene transfer into stem cells. Mol. Pharm.3(2), 95–103 (2006).
   PubMed Web of Science ®Google Scholar
• Burdelya LG, Krivokrysenko VI, Tallant TC et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science320(5873), 226–230 (2008).
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol.29(6 Suppl. 16), 15–18 (2002).
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Tanaka N, Numunaitis JJ et al. Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: evaluation of biodistribution and immune response. J. Clin. Oncol.26(155), 3572 (2008).
   Google Scholar
• Nemunaitis J, Tong AW, Nemunaitis M et al. A Phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin), for various solid tumors. Mol. Ther.18(2), 429–434 (2010).
   PubMed Web of Science ®Google Scholar
• DeWeese TL, van der Poel H, Li S et al. A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res.61(20), 7464–7472 (2001).
   PubMed Web of Science ®Google Scholar
• Small EJ, Carducci MA, Burke JM et al. A Phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther.14(1), 107–117 (2006).
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Iwado E, Kondo Y et al. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther.15(17), 1233–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Okada N, Tsukada Y, Nakagawa S et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem. Biophys. Res. Commun.282(1), 173–179 (2001).
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Kagawa S, Kishimoto H et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int. J. Cancer119(2), 432–440 (2006).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Hioki M, Fujiwara T et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp. Cell Res.312(3), 256–265 (2006).
   PubMed Web of Science ®Google Scholar
• Liu D, Kojima T, Ouchi M et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol. Cancer Ther.8(4), 980–987 (2009).
   PubMedGoogle Scholar
• Fujiwara T, Tanaka N, Kanazawa S et al. Multicenter Phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.24(11), 1689–1699 (2006).
   PubMed Web of Science ®Google Scholar
• Sakai R, Kagawa S, Yamasaki Y et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol. Cancer Ther.9(6), 1884–1893 (2010).
   PubMed Web of Science ®Google Scholar